KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Other Non Operating Income (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Other Non Operating Income for 17 consecutive years, with -$60.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 14.77% to -$60.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$86.8 million, a 5526.0% decrease, with the full-year FY2025 number at $1.2 million, down 25.0% from a year prior.
  • Other Non Operating Income was -$60.5 million for Q4 2025 at Bio-Rad Laboratories, down from $8.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $50.4 million in Q1 2023 to a low of -$1.3 billion in Q4 2023.
  • A 5-year average of -$70.8 million and a median of $4.4 million in 2022 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: soared 6810.0% in 2022, then tumbled 167362.5% in 2023.
  • Bio-Rad Laboratories' Other Non Operating Income stood at $10.8 million in 2021, then crashed by 107.41% to -$800000.0 in 2022, then crashed by 167362.5% to -$1.3 billion in 2023, then surged by 96.07% to -$52.7 million in 2024, then dropped by 14.77% to -$60.5 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Other Non Operating Income are -$60.5 million (Q4 2025), $8.3 million (Q3 2025), and -$52.7 million (Q4 2024).